WallStreetZenWallStreetZen

NASDAQ: HOOK
Hookipa Pharma Inc Stock

Open Broker Account
$0.84-0.04 (-4.55%)
Updated Dec 8, 2022
HOOK Price
$0.84
Fair Value Price
$2.22
Market Cap
$45.96M
52 Week Low
$0.80
52 Week High
$3.13
P/E
-0.55x
P/B
0.41x
P/S
7.11x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.32M
Earnings
-$73.84M
Gross Margin
100%
Operating Margin
-707.95%
Profit Margin
-715.8%
Debt to Equity
0.34
Operating Cash Flow
-$46M
Beta
1.29
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

HOOK Overview

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HOOK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HOOK ($0.84) is undervalued by 62.2% relative to our estimate of its Fair Value price of $2.22 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HOOK ($0.84) is significantly undervalued by 62.2% relative to our estimate of its Fair Value price of $2.22 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
HOOK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HOOK due diligence checks available for Premium users.

Be the first to know about important HOOK news, forecast changes, insider trades & much more!

HOOK News

Valuation

HOOK fair value

Fair Value of HOOK stock based on Discounted Cash Flow (DCF)
Price
$0.84
Fair Value
$2.22
Undervalued by
62.20%
HOOK ($0.84) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HOOK ($0.84) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HOOK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

HOOK price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.55x
Industry
13.31x
Market
21.39x

HOOK price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.41x
Industry
4.98x
HOOK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HOOK's financial health

Profit margin

Revenue
$2.2M
Net Income
-$18.3M
Profit Margin
-819.7%
HOOK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HOOK's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$151.5M
Liabilities
$38.2M
Debt to equity
0.34
HOOK's short-term assets ($129.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HOOK's short-term assets ($129.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HOOK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$16.5M
Investing
-$958.0k
Financing
$127.0k
HOOK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

HOOK vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
HOOK$45.96M-4.00%-0.55x0.41x
TCRR$45.62M-7.09%-0.38x0.23x
LPTX$46.44M-2.29%-1.04x0.66x
RFL$46.50M-2.06%-0.30x0.46x
SYBX$46.54M-1.93%-0.76x0.46x

Hookipa Pharma Stock FAQ

What is Hookipa Pharma's quote symbol?

NASDAQ: HOOK) Hookipa Pharma trades on the NASDAQ under the ticker symbol HOOK. Hookipa Pharma stock quotes can also be displayed as NASDAQ: HOOK.

If you're new to stock investing, here's how to buy Hookipa Pharma stock.

What is the 52 week high and low for Hookipa Pharma (NASDAQ: HOOK)?

(NASDAQ: HOOK) Hookipa Pharma's 52-week high was $3.13, and its 52-week low was $0.80. It is currently -73.16% from its 52-week high and 5% from its 52-week low.

How much is Hookipa Pharma stock worth today?

(NASDAQ: HOOK) Hookipa Pharma currently has 54,716,655 outstanding shares. With Hookipa Pharma stock trading at $0.84 per share, the total value of Hookipa Pharma stock (market capitalization) is $45.96M.

Hookipa Pharma stock was originally listed at a price of $14.00 in Apr 18, 2019. If you had invested in Hookipa Pharma stock at $14.00, your return over the last 3 years would have been -94%, for an annualized return of -60.85% (not including any dividends or dividend reinvestments).

How much is Hookipa Pharma's stock price per share?

(NASDAQ: HOOK) Hookipa Pharma stock price per share is $0.84 today (as of Dec 8, 2022).

What is Hookipa Pharma's Market Cap?

(NASDAQ: HOOK) Hookipa Pharma's market cap is $45.96M, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Hookipa Pharma's market cap is calculated by multiplying HOOK's current stock price of $0.84 by HOOK's total outstanding shares of 54,716,655.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.